Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess time window, efficacy and safety of patients who
receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid
tumor.